ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • 3
  • …
  • 74
  • Next Page »
Search Again »
  • Abstract Number: L21 • ACR Convergence 2021

    Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial

    Benjamin Terrier1, Gregory Pugnet2, Claire de Moreuil3, Bernard Bonnotte4, Ygal Benhamou5, Elisabeth Diot6, Dominique Chauveau2, Pierre Duffau7, Nicolas Limal8, Antoine Neel9, Geoffrey Urbanski10, Noemie Jourde-Chiche11, Nicolas Martin-Silva12, Francois Maurier13, Arsene Mekinian14, Nicolas Schleinitz11, Felix Ackermann15, Anne-Laure Fauchais16, Antoine Froissart17, Thomas Le Gallou18, Yurdagul Uzunhan19, Jean-Francois Viallard7, Alice Berezne20, Laurent Chiche21, Bruno Crestani14, Guillaume Direz22, Cecile-Audrey Durel23, Pascal Godmer24, Jean-Emmanuel Kahn25, Marc Lambert26, Thomas Quemeneur27, Jacques Cadranel14, Pierre Charles28, Antoine Dossier14, Lea Jilet29, Loic Guillevin14, Hendy Abdoul29 and Xavier Puechal14, 1Cochin Hospital, Paris, France, 2CHU, Toulouse, France, 3CHU, Brest, France, 4CHU, Dijon, France, 5CHU, Rouen, France, 6CHU, Tours, France, 7CHU, Bordeaux, France, 8CHU, Creteil, France, 9CHU, Nantes, France, 10CHU, Angers, France, 11CHU, Marseille, France, 12CHU, Caen, France, 13CH, Metz, France, 14CHU, Paris, France, 15Hopital Foch, Suresnes, France, 16CHU, Limoges, France, 17CHIC, Creteil, France, 18CHU, Rennes, France, 19CHU, Bobigny, France, 20CH, Annecy, France, 21CH, Marseille, France, 22CH, Le Mans, France, 23CHU, Lyon, France, 24CH, Vannes, France, 25CHU, Boulogne, France, 26CHRU, Lille, France, 27CH, Valenciennes, France, 28CH, Paris, France, 29URC, Paris, France

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic ANCA-associated vasculitis.Glucocorticoids, alone or in combination with cyclophosphamide in severe forms, induce remission in most patients…
  • Abstract Number: L13 • ACR Convergence 2021

    Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study

    Cynthia Aranow1, Cornelia Allaart2, Zahir Amoura3, Ian N Bruce4, Patricia Cagnoli5, Richard Furie1, Paul Peter Tak6, Murray Urowitz7, Ronald van Vollenhoven8, Kenneth L Clark6, Mark Daniels9, Norma Lynn Fox10, Yun Irene Gregan10, James Groark11, Robert B Henderson9, Mary Oldham9, Don Shanahan9, Andre van Maurik9, David A Roth10 and YK Onno Teng2, 1Feinstein Institutes for Medical Research, Northwell Health, Great Neck, NY, 2Leiden University Medical Center, Leiden, Netherlands, 3Centre National de reference pour le Lupus, Service de Medecine Interne 2, Institut E3M, Hopital Pitié-Salpétrière, Paris, France, 4NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Trust and Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 5University of Michigan Medical Center, Ann Arbor, MI, 6GlaxoSmithKline (At the time of the author's contribution to this study), Stevenage, United Kingdom, 7Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 8Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 9GlaxoSmithKline, Stevenage, United Kingdom, 10GlaxoSmithKline, Collegeville, PA, 11GlaxoSmithKline (At the time of the author's contribution to this study), Collegeville, PA

    Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated…
  • Abstract Number: 0032 • ACR Convergence 2021

    IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis

    Adela Navratilova1, Lucie Andrés Cerezo1, Hana Hulejová2, Viktor Bečvář2, Michal Tomcik3, Dana Tegzova2, Martina Olejárová1, David Veigl4, Karel Pavelka3, Jiri Vencovsky2 and Ladislav Senolt3, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 4First Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Interleukin 40 (IL-40) is recently identified B cell - associated cytokine implicated in humoral immune responses and in B cell development and homeostasis. As…
  • Abstract Number: 0102 • ACR Convergence 2021

    Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients

    Anne Regierer1, Rebecca Hasseli2, Martin Schaefer1, Bimba Franziska Hoyer3, Andreas Krause4, Hanns-Martin Lorenz5, Alexander Pfeil6, Jutta Richter7, Tim Schmeiser8, Anja Strangfeld9, Hendrik Schulze-Koops10, Reinhard Voll11, Christof Specker12 and Ulf Müller-Ladner13, 1German Rheumatism Research Center, Berlin, Germany, 2Justus-Liebig-University Giessen, Bad Nauheim, Germany, 3Universittsklinikum Schleswig-Holstein, Kiel, Germany, 4Immanuel Hospital, Berlin, Germany, 5University Hospital Heidelberg Germany, Heidelberg, Germany, 6Friedrich Schiller University Jena, Jena, Germany, 7Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, 8Private Practice, Cologne, Germany, 9Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 10Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, 11Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, 12Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, 13JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany

    Background/Purpose: Due to the impressive efforts of the global scientific rheumatology community, increasing evidence about inflammatory rheumatic and musculoskeletal diseases (RMD) specific risk factors in…
  • Abstract Number: 0321 • ACR Convergence 2021

    Sequential Administration of Belimumab and Rituximab in Primary Sjögren’s Syndrome Reduces Minor Salivary Gland–Resident B Cells and Delays B-Cell Repopulation in Circulation

    André van Maurik1, David Gardner2, Saba Nayar2, Charlotte Smith2, Kenneth Clark1, Prafull Mistry1, Rajesh Punwaney3, David Roth3, Robert Henderson1, Xavier Mariette4 and Francesca Barone2, 1GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 2University of Birmingham, College of Medical and Dental Sciences, Birmingham, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by B-cell hyperactivity and elevated serum and saliva B-lymphocyte stimulator (BLyS) levels.1 Sequential administration of belimumab (BEL; anti-BLyS)…
  • Abstract Number: 0416 • ACR Convergence 2021

    Pharmacological Response of Rituximab Based on Dose Intensity in Maintenance Therapy of ANCA-Associated Vasculitis

    Jason Springer1 and Ryan Funk2, 1Vanderbilt University Medical Center, Franklin, TN, 2University of Kansas Medical Center, Kansas City, KS

    Background/Purpose: Rituximab (RTX) has demonstrated efficacy in maintenance therapy in ANCA-associated vasculitis. However, different dosing protocols have been used in clinical trials and there is…
  • Abstract Number: 0437 • ACR Convergence 2021

    Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab

    Victoria Furer1, Tali Eviatar2, Devy Zisman3, Hagit Peleg4, Daphna Paran5, David Levartovsky1, Ilana Kaufman6, Michael Zisapel1, Ofir Elalouf7, Roni Meidan1, Adi Broyde8, Ari Polachek9, Jonathan Wollman7, Katya Meridor10, Hila Nochomovitz1, Adi Silberman1, Dana Rosenberg1, Joy Feld11, Amir Haddad12, Tal Gazitt13, Muna Elias3, Nizar Hijaze14, Fadi Kharouf4, Gabi Shefer1, Orly Sharon1, Sara Pel1, Sharon Nevo1 and Ori Elkayam15, 1Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Givataim, Israel, 3Carmel Medical Center, Haifa, Israel, 4Hadassah Medical Center, Jerusalem, Israel, 5Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, 6Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, 7Tel Aviv Medical Center, Herzliya, Israel, 8Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, 9Sourasky Medical Center, Petah-Tikva, Israel, 10Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, 11Carmel and Zvulun Medical Centre, Haifa, Israel, 12Carmel Medical Centre, Haifa, Israel, 13Carmel Hospital, Haifa, Israel, 14Carmel medical centre, Tamra, Israel, 15Tel Aviv Medical Center, Tel Aviv, Israel

    Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
  • Abstract Number: 0496 • ACR Convergence 2021

    Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)

    Satoshi Ebata1, Ayumi Yoshizaki1, Koji Oba2, Kosuke Kashiwabara3, Keiko Ueda3, Yukari Umemura4, Takeyuki Watadani5, Takemichi Fukasawa1, Shunsuke Miura1, Asako Yoshizaki-Ogawa1, Yoshihide Asano1, Naoko Okiyama6, Masanari Kodera7, Minoru Hasegawa8 and Shinichi Sato1, 1Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, 2Department of Biostatistics, School of Public Health, Graduate School of Medicine, and Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, 3Clinical Research Support Center, The Tokyo University Hospital, Tokyo, Japan, 4Biostatistics Section, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, 5Department of Diagnostic Radiology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, 6Department of Dermatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Ibaraki, Japan, 7Department of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Aichi, Japan., Aichi, Japan, 8Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan., Fukui, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease belonging to collagen diseases, characterized by fibrosis of various organs including the skin and lungs, and…
  • Abstract Number: 0648 • ACR Convergence 2021

    Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative

    Beth Rutstein1, Melissa Argraves2, Atiye Bilgic Dagci2, Sarah Bayefsky2, Julia Rood2, Julie Chase3, Jay Mehta2, Melissa Lerman2, Cory Stingl4 and Jon Burnham2, 1Children's Hospital of Philadelphia, Wynnewood, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3The Children's Hospital of Philadelphia, Philadelphia, PA, 4Children's Hospital of Philadelphia, Durham, NC

    Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
  • Abstract Number: 0649 • ACR Convergence 2021

    Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention

    Daniel Magliulo1, Stefanie Wade2 and Vasileios Kyttaris3, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3BIDMC, Boston, MA

    Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
  • Abstract Number: 0835 • ACR Convergence 2021

    Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice

    Jerome Avouac1, Rodolphe Cougnaud-Murail1, Claire Goulvestre2, Sophie Dumas3, Anna Molto4, Corinne Miceli-Richard5, ornella conort3, Frederic Batteux2 and Yannick Allanore1, 1Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, 2Université de Paris, Service d'Immunologie, Hôpital Cochin, AP-HP.CUP, Paris, France, 3Université de Paris, Service de pharmacie, Hôpital Cochin, AP-HP.CUP, Paris, France, 4Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, 5Assistance Publique Hpitaux de PAris, Paris, France

    Background/Purpose: To study in daily practice the risk of immunogenicity of patients treated with rituximab (RTX) biosimilar GP2013 for their chronic inflammatory rheumatic disorder.Methods: A…
  • Abstract Number: 0954 • ACR Convergence 2021

    The Association of Rituximab- vs. Cyclophosphamide-Based Remission Induction Strategies with Risk of End-Stage Renal Disease and Death in ANCA-Associated Vasculitis

    Zachary Wallace1, Xiaoqing Fu2, Claire Cook3, Yuqing Zhang4, John Stone5 and Hyon K. Choi6, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, 4Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 6Massachusetts General Hospital, Lexington, MA

    Background/Purpose: The RAVE trial established the non-inferiority of rituximab (RTX) vs cyclophosphamide (CYC) for remission induction of ANCA-Associated Vasculitis (AAV). Patients in RAVE were followed…
  • Abstract Number: 0964 • ACR Convergence 2021

    Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases

    Samuel Bitoun1, Julien Henry2, Christelle Vauloup Fellous3, Raphaele Seror4, Lina Mouna3, Candie Joly5, Delphine Desjardins5, Marie Bitu5, Roger Le Grand6, Anne-Marie Roque Afonso3 and Xavier Mariette7, 1Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, 2Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Le Plessis Robinson, France, 3AP–HP, Hôpital Paul-Brousse, Department of Virology, University Paris Saclay, INSERM U1193,, Villejuif, France, 4Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184, FHU CARE FHU CARE, Le kremlin Bicetre, France, 5Paris-Saclay University, Inserm UMR 1184, FHU CARE, CEA, Le Kremlin Bicêtre, France, 6UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, Fontenay Aux Roses, France, 7Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…
  • Abstract Number: 0987 • ACR Convergence 2021

    Rituximab Prevents the Progression of B-cell Driven Inflammatory Infiltrate in the Minor Salivary Glands of Primary Sjogren’s Syndrome by Downregulating Immunological Pathways Key in Ectopic Germinal Centre Organization: Results from the TRACTISS Trial

    Elena Pontarini1, Farzana Chowdhury1, Elisabetta Sciacca1, Sofia Grigoriadou1, Felice Rivellese1, Davide Lucchesi1, Katriona Goldmann1, Liliane Fossati-Jimack1, Paul Emery2, Wan-Fai NG3, Nurhan Sutcliffe4, Colin C Everett5, Catherine Fernandez5, Anwar Tappuni6, Myles Lewis1, Costantino Pitzalis7, Simon J Bowman8 and Michele Bombardieri1, 1Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, 3Translational and Clinical Research Institute, Newcastle University,, Newcastle, United Kingdom, 4Royal London Hospital, Bart’s Health NHS Trust, London, United Kingdom, 5Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom, 6Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Queen Mary University of London, London, United Kingdom, 7Queen Mary University of London, London, United Kingdom, 8Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: The pathogenic role of B-cells in primary Sjögren’s Syndrome (pSS) is well established and B cell abnormalities are hallmarks of the disease. Because of…
  • Abstract Number: 1224 • ACR Convergence 2021

    Low CD39 Expression on B Cells Predicts the Occurrence of Anti-Drug Antibodies in RA Patients Treated with Rituximab

    Samuel Bitoun1, Bineta Ly2, Signe Hässler3, Audrey Paoletti4, Aude Gleizes5, Salima Hacein-Bey5, Philippe Bröet3, Marc Pallardy6 and Xavier Mariette7, 1Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, 2INSERM U1184, Université Paris Saclay, Le Kremlin Bicêtre, France, 3CESP, INSERM UMR 1018, Universite Paris-Saclay, Villejuif, France, 4INSERM U1184, Université Paris Saclay, le kremlin bicetre, France, 5Hôpital Bicètre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre, France, 6Faculté de Pharmacie, Université Paris-Saclay, Chatenay Mallabry, France, 7Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: Anti-Drug antibodies (ADAb) are well studied and have an impact on response to treatment with monoclonal anti-TNF biologics. Rituximab treatment has an important immunogenic…
  • 1
  • 2
  • 3
  • …
  • 74
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies